HIV/AIDS Vaccine Clinical Trial Results Revealed

Abacavir – a nucleoside analog reverse transcriptase inhibitor (NARTI or NRTI).

HIV/AIDS clinical trial results revealed two ways the immune system can respond, scientists announced Tuesday. The trial, called RV144, could predict whether patients vaccinated will be protected or likely become infected with HIV, reported CNN’s health blog “The Chart.”

The results were announced at the AIDS Vaccine conference in Bangkok, which is hosted by the Global HIV Vaccine Enterprise. The clinical trial was conducted at Mahidol University and Thailand’s Ministry of Public Health in 2009.

Scientists analyzed the results for more than three years and determined that the vaccine prevented infection in roughly 30 percent of the 16,000 healthy Thai participants who received the vaccine compared to those who received a placebo.

"Vaccine recipients with high levels of one type of antibody response had the lowest rate of HIV infection, and those with high levels of another type had the highest rate of infection,” said Dr. Barton Haynes, Director of the Duke Human Vaccine Institute at Duke University School of Medicine, who also coordinated the follow-up study the trial data, according to “The Chart.”

Study investigators called the results “modestly protective” and suggested the study provided proof that a vaccine might me possible.

"We now have an informed hypothesis, we have signals.  Now we know where we want to go,” said Haynes, according to “The Chart.”

Print Article